PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
rs1057519824 in
MET gene and
Neoplasms
PMID 17483355 2007 An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
rs28933369 in
MIR4728;ERBB2 gene and
Neoplasms
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
rs1057519851 in
MYC gene and
Neoplasms
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
rs121918683 in
MYC;CASC11 gene and
Neoplasms
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
rs121434596 in
NRAS gene and
Neoplasms
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
rs121913279 in
PIK3CA gene and
Neoplasms
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
rs1057519757 in
PIK3R1 gene and
Neoplasms
PMID 19962457 2010 Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 24651012 2014 Mutant p53 in cancer: new functions and therapeutic opportunities.
PMID 17015838 2006 Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.
PMID 11101847 2000 Role of the p53-homologue p73 in E2F1-induced apoptosis.
PMID 18391940 2008 p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation.
rs104893829 in
VHL gene and
Neoplasms
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.